Zhang X, Song Y H, Gao X B, Hu K, Zhang Y Z, Gao K, Zhang X L
Zhongshan Ophthalmic Centre, Sun Yat-sen University, State Key Laboratory of Ophthalmology, Guangzhou 510060, China.
Zhonghua Yan Ke Za Zhi. 2022 Jan 11;58(1):63-68. doi: 10.3760/cma.j.cn112142-20210904-00410.
Glaucoma is the leading irreversible blinding eye disease worldwide, and China has the largest amount of primary angle-closure glaucoma (PACG). To reduce blindness, the therapeutic evolution can play a role. With the technical development of minimally invasive glaucoma surgery (MIGS), the treatment of angle-closure glaucoma has been in a transformation. This article reviews the literatures related to the advances of MIGS in the combined treatment of PACG. The research findings show that MIGS may become one of the preferred surgical treatments for PACG in the future clinical management of glaucoma.
青光眼是全球首要的不可逆致盲眼病,而中国原发性闭角型青光眼(PACG)患者数量最多。为减少失明,治疗进展能发挥作用。随着微创青光眼手术(MIGS)技术的发展,闭角型青光眼的治疗正在发生变革。本文综述了与MIGS在PACG联合治疗中的进展相关的文献。研究结果表明,在未来青光眼的临床管理中,MIGS可能成为PACG首选的手术治疗方法之一。